QuantiFERON®-TB gold in-tube performance for diagnosing active tuberculosis in children and adults in a high burden setting. by Rose, Michala V. et al.
QuantiFERONH-TB Gold In-Tube Performance for
Diagnosing Active Tuberculosis in Children and Adults in
a High Burden Setting
Michala V. Rose1,2*, Godfather Kimaro3, Thomas N. Nissen2, Inge Kroidl4,5, Michael Hoelscher5,
Ib C. Bygbjerg1, Sayoki G. Mfinanga3, Pernille Ravn6
1Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark, 2Clinical Research Centre, University Hospital
Hvidovre, Hvidovre, Denmark, 3Muhimbili Medical Research Centre, National Institute for Medical Research, Dar es Salaam, Tanzania, 4NIMR-Mbeya Medical Research
Programme, Mbeya, Tanzania, 5Department of Infectious Diseases and Tropical Medicine, Klinikum of the University of Munich, Munich, Germany, 6Department for
Infectious Diseases, University Hospital Odense, Odense, Denmark
Abstract
Aim: To determine whether QuantiFERONH-TB Gold In-Tube (QFT) can contribute to the diagnosis of active tuberculosis (TB)
in children in a high-burden setting and to assess the performance of QFT and tuberculin skin test (TST) in a prospective
cohort of TB suspect children compared to adults with confirmed TB in Tanzania.
Methods: Sensitivity and specificity of QFT and TST for diagnosing active TB as well as indeterminate QFT rates and IFN-c
levels were assessed in 211 TB suspect children in a Tanzanian district hospital and contrasted in 90 adults with confirmed
pulmonary TB.
Results: Sensitivity of QFT and TST in children with confirmed TB was 19% (5/27) and 6% (2/31) respectively. In adults
sensitivity of QFT and TST was 84% (73/87) and 85% (63/74). The QFT indeterminate rate in children and adults was 27% and
3%. Median levels of IFN-c were lower in children than adults, particularly children ,2 years and HIV infected. An
indeterminate result was associated with age ,2 years but not malnutrition or HIV status. Overall childhood mortality was
19% and associated with an indeterminate QFT result at baseline.
Conclusion: QFT and TST showed poor performance and a surprisingly low sensitivity in children. In contrast the
performance in Tanzanian adults was good and comparable to performance in high-income countries. Indeterminate results
in children were associated with young age and increased mortality. Neither test can be recommended for diagnosing
active TB in children with immature or impaired immunity in a high-burden setting.
Citation: Rose MV, Kimaro G, Nissen TN, Kroidl I, Hoelscher M, et al. (2012) QuantiFERONH-TB Gold In-Tube Performance for Diagnosing Active Tuberculosis in
Children and Adults in a High Burden Setting. PLoS ONE 7(7): e37851. doi:10.1371/journal.pone.0037851
Editor: Lorenz von Seidlein, Menzies School of Health Research, Australia
Received January 15, 2012; Accepted April 27, 2012; Published July 12, 2012
Copyright:  2012 Rose et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was financially supported by the KNCV Tuberculosis Foundation, Reinholdt Jorck’s Fund, Cluster in International Health, Justesen’s Fund,
Danish Research Council and Danish International Development Assistance (74-08-UHH DANIDA). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts to declare: Pernille Ravn has been an invited speaker by
Cellestis and has received QFT-IT kits at a reduced price for nonprofit research. Hvidovre Hospital has filed patents on the use of IP-10 as a marker for infection
with Mycobacterium tuberculosis. Pernille Ravn is one of the registered co-inventors. This does not alter the authors’ adherence to all the PLoS ONE policies on
sharing data and materials.
* E-mail: michala.rose@gmail.com
Introduction
The aim of this study was to investigate the potential of the
interferon-c release assay (IGRA) QuantiFERONH-TB Gold In-
Tube (QFT) (Cellestis Limited Chadstone, Australia) as a reliable
diagnostic tool for physicians in Tanzania, a high TB burden
country, with considerable prevalence of HIV and malnutrition,
for diagnosing active TB in children.
TB is a major contributor to childhood morbidity and mortality,
with children ,5 years at highest risk and 40–50% of infected
infants developing disease within 1–2 years [1,2]. However
childhood TB is notoriously difficult to confirm, due to its pauci-
bacillary nature, and existing tools have limited performance [3].
In TB endemic countries, diagnosis is usually a clinical
diagnosis, relying on recognition of clinical features, suggestive
chest x-ray (CXR) and if available a positive tuberculin skin test
(TST) [4]. However it can be difficult to distinguish between the
signs and symptoms of TB, HIV and malnutrition, and CXRs and
TST results can be difficult to interpret [5,6].
QFT relies on M.tuberculosis (MTB) specific T-cell responses,
measuring levels of interferon-gamma (IFN-c) released in whole
blood in response to stimulation with the MTB specific antigens:
ESAT-6, CFP-10 and TB7.7, indicating past or present infection.
IGRAs are generally more specific than TST, since they do not
cross-react with the BCG vaccine, M.avium or most other non-
tuberculous mycobacteria (NTM). IGRAs are increasingly being
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used worldwide as an alternative to, or in conjunction with, TST
[7] for diagnosing latent TB and although not directly diagnostic
for active TB, IGRAs are often used by clinicians as an additional
tool in the diagnosis of active TB [8]. However there is a lack of
evidence of the performance in children, especially in young
children in a high burden setting [9].
In this study the performance of QFT was assessed in terms of
sensitivity, specificity, indeterminate rates, median IFN-c levels
and risk factor analysis for positive and indeterminate results.
Performance of TST for diagnosing active TB was included for
comparison. Considering the diagnostic challenges in children and
difficulties in assuring a gold standard of confirmed TB, adults
with confirmed active TB, from the same location, were included
as a measure of contrast.
Methods
Ethics Statement
The study protocol was approved by the Tanzanian Medical
Research Coordinating Committee (NIMR/HQ/R.8a/Vol IX/
584) and was evaluated by the Danish Central Ethical Committee
without any objections. Written informed consent was obtained
from the immediate caretaker, or next of kin, prior to inclusion, on
behalf of children participating in the study. The standards for
reporting diagnostic accuracy studies (STARD) criteria were
followed in reporting the results.
Study Setting and Population
The study participants were recruited prospectively at Muheza
designated district hospital, Tanga, Tanzania. Muheza is a rural
district with a population of 209.480, where 90% are engaged in
peasantry, fishery and small-scale business [10]. The TB
notification rate in the district in 2009 was 431/100.000 [11].
Children ,15 years with TB suspect signs and symptoms were
included consecutively from the paediatric ward and outpatients
departments, including the HIV, TB, and mother-child clinics.
Adults with active TB were included consecutively from the TB
clinic. Inclusion criteria are listed in Box S1.
A standardized questionnaire was used to record demographic
and clinical details of the participants, including age, weight,
height, TB specific signs and symptoms and presence of BCG scar.
For the children additional information was collected about
history of BCG vaccine, TB exposure, response to prior antibiotic
treatment and history of health facility visits.
All the study participants provided blood for QFT and HIV
testing. Chest x-rays and TST were performed and either sputum
or gastric wash samples were sent for microscopy and culture
examination. Follow-up of the children was conducted 2 and 6
months after inclusion, involving a standardised clinical examina-
tion and questionnaire concerning health status since last
examination. Children who did not return for follow-up were
traced within 7–12 months of inclusion.
Figure 1. Summary of recruitment and diagnostic classification of children. * Children without follow-up data were excluded since they
could not be classified according to the TB classifications. However one child had culture confirmed TB and could therefore be classified without
follow-up data. ** The first 61 QFT results were excluded, when the initial QFT analysis showed very poor response in all the QFT tubes, including the
mitogen. This was attributed to incorrect storage in a room reaching temperatures above 30uC. Subsequent tubes were all stored at 5–10uC.
doi:10.1371/journal.pone.0037851.g001
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Interferon Gamma Release Assay (IGRA)
Venous blood was collected in a syringe and immediately
dispensed into the QFT tubes, Nil (negative control coated with
saline), TB-Ag (coated with MTB specific antigens) and Mitogen
(positive control coated with phytohaemaggluttin), according to
the manufacturer’s instructions (Cellestis Ltd). The tubes were
taken to the laboratory within 4 hours and incubated at 37uC for
16–24 hours.
Immediately after incubation the samples were centrifuged and
the supernatants stored at minus 70uC, until IFN-c was measured
using the QFT ELISA at the NIMR-Mbeya Medical Research
Programme laboratory, Tanzania. The results were reported as
positive, negative or indeterminate according to the manufactur-
er’s instructions. In addition the raw quantitative results were
recorded.
The results of the first 61 QFT tests revealed that 82% of the
results were indeterminate with poor response in all the QFT
tubes. Thorough quality assurance of all the test procedures
indicated that the tubes had been stored under conditions with
temperatures reaching above 30uC. This was considered to be the
most likely the reason for the high number of indeterminate
results. All the tubes were replaced and new tubes were stored at
5–10uC, until the time they were used.
Tuberculin Skin Testing (TST)
Two units of purified protein derivate RT23 from Staten
Serum Institute, Denmark, were administered intradermally
using the mantoux technique recommended by the manufac-
turer. The transverse diameter of the induration was recorded
in millimetres after 48–72 hours. An induration of $5 mm was
considered positive in HIV positive children and adults whilst
an induration of $10 mm was considered positive for all others.
Chest X-Ray (CXR)
The children were chest x-rayed at inclusion. The CXRs were
read by three experts; the hospital radiologist and two independent
senior radiologists, who were unaware of the clinical status of the
child. Using a standardised recording form, the CXRs were
classified as either certain TB, highly suggestive TB, uncertain or
not TB, based on TB specific or suggestive features. CXRs from
202 children were included.
Microbiology
Sputum or gastric wash samples were collected from the
children on three consecutive mornings. Gastric wash samples
were collected in containers containing 100 mg sodium carbonate.
Ascites samples were included for 2 patients, whilst no cerebro-
spinal fluid or lymph node samples were included. The adults were
initially diagnosed with smear positive TB at the Muheza district
hospital laboratory using the Ziehl-Neelsen staining technique for
acid fast bacteria. An extra sputum sample was collected from the
adults for confirmation of diagnosis. All the gastric wash and
sputum samples were refrigerated, on average 4 days, until they
were sent for confirmatory microscopy and culture at the Central
TB Reference Lab, Dar es Salaam (CTRL) where auramine
staining was used for fluorescence microscopy and Lo¨wenstein-
Jensen media for culture. Para-nitrobenzoic acid, which inhibits
MTB but not NTMs, was added in positive samples to exclude
NTMs.
Table 1. Characteristics of study population.
Children all Confirmed Possible Not TB Adults
N=211 N=33 N=85 N=93 N=90
Age mean yrs (SD) 4.4 (3.8) 4.7 (3.7) 4.1 (3.9) 4.5 (3.7) 39.5 (14.9)
Age groups n (%)
,2 yrs 77 (37) 7 (21) 36 (42) 34 (37) – –
2–4.9 yrs 53 (25) 13 (40) 21 (25) 19 (20) – –
5–9.9 yrs 51 (24) 8 (24) 15 (18) 28 (30) – –
.10 yrs 30 (14) 5 (15) 13 (15) 12 (13) – –
Male n (%) 124 (59) 24 (73) 47 (55) 53 (57) 72 (80)
HIV Positive { n (%) 78 (37) 18 (55) 38 (45) 22 (24) 25 (28)
Z-score #22 { n (%) 109 (58) 15 (47) 45 (63) 49 (58) – –
BMI ,18.5 n (%) – – – – – – – – 57 (63)
History contact { n (%) 72 (35) 13 (39) 30 (36) 29 (32) – –
BCG history n (%) 196 (93) 30 (91) 81 (95) 85 (91) – –
BCG scar n (%) 192 (91) 28 (85) 75 (88) 89 (96) 70 (78)
Clinical TB * n (%) 76 (34) 33 (100) 43 (51) 0 0 90 (100)
Follow-up status{n (%)
Healthy 152 (72) 31 (97) 28 (33) 93 (100) – –
Still ill 19 (9) – – 19 (22) 0 0 – –
Dead 39 (19) 1 (3) 38 (45) 0 0 – –
{HIV test result available for 209 children, weight-for-age Z-score data available for 188 children, history of contact data available for 208 children (reported contact to
case of TB in last 2 years), 1 child with confirmed TB did not have follow-up data (follow-up status defined as health status of child 6 months after inclusion into study).
*Clinical TB in children defined as active TB diagnosed by local physician based on clinical examination, CXR and TST. Clinical TB in adults defined as active TB diagnosed
by local physician, all included adults had positive Ziehl-Neelsen smear microscopy as well as either positive culture and/or positive fluorescence microscopy.
doi:10.1371/journal.pone.0037851.t001
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TB Diagnosis and Classification
The clinical TB diagnosis in children and the decision to start
anti-TB treatment was made by the district TB medical doctor or
the medical doctor in charge of the paediatric ward. The study
team was not involved other than ensuring that the TB medical
doctor was consulted on each case and providing the results of
CXR, TST and HIV test. The results of the QFT test were not
available to the physicians responsible for diagnosing or treating
the children.
Each child was assigned to one of four predefined diagnostic
classifications; ‘‘Microbiologically confirmed TB’’, ‘‘Highly prob-
able TB’’, ‘‘Possible TB’’ and ‘‘Not TB’’. The classifications were
based on microscopy and culture data, CXR results, clinical
examination and follow-up data (Box S2). For data analysis
children with microbiologically confirmed TB and highly probable
TB were considered to have confirmed TB. Children without
follow-up data were excluded, unless they had microbiologically
confirmed TB. Adults with either positive culture or positive
fluorescence microscopy were classified as confirmed TB.
Data Management and Statistical Analysis
Data were double-entered into a data entry database using MS-
Access (Microsoft Corp, VA, USA) including error, range and
consistency check programs. Statistical analyses were performed
using StataTM v 10.0 (Stata Corp, TX, USA). Epi InfoTM 3.5.2
(CDC, USA) was used to generate weight-for-age z-scores to assess
nutritional status in children.
Indeterminate results were excluded in the sensitivity and
specificity analysis as well as in the risk factor analysis for a positive
QFT result. Student’s t-test was used to compare means,
Wilcoxon’s rank-sum test for comparing medians, using log
transformation for data that was not normally distributed.
Logistic regression analysis was used for univariable and
multivariable analysis of risk factors’ association with positive
Table 2. Median IFN-c U/ml in all three Quantiferon TB Gold
In-Tube tubes in children and adults.
Children Negative control Positive control TB antigens
IFN-c U/ml (IQR) IFN-c U/ml (IQR)
IFN-c U/ml
(IQR)
All (TB suspect) 0.15* (0.09–0.35) 2.05* (0.6–7.53) 0.19* (0.1–0.55)
Confirmed TB 0.15* (0.12–0.26) 3.8 (1.08–7.26) 0.17* (0.10–0.48)
Possible TB 0.13* (0.08–0.27) 1.69* (0.44–7.33) 0.17* (0.10–0.56)
Not TB 0.19* (0.09–0.38) 2.26 (0.80–7.61) 0.19* (0.11–0.55)
Adults
Confirmed TB 0.36 (0.22–0.59) 2.63 (1.29–8.09) 3.28(0.99–6.58)
Comparison of median IFN-c values in the three QFT tubes in children and
adults according to diagnostic TB classificaiton. There were significantly lower
levels* (p,0.05) in all subgroups of children compared to adults, except in the
positive control where median levels in children with confirmed and not TB
were not significantly different to levels in adults.
Wilcoxon’s rank-sum test used to test difference between median IFN-c in
children and adults.
IQR: interquartile range.
doi:10.1371/journal.pone.0037851.t002
Table 3. Comparison of median IFN-c responses in all TB suspect children.
Negative control Positive control TB antigens
IFN-c U/ml (IQR) p-value{ IFN-c U/ml (IQR) p-value{ IFN-c U/ml (IQR) p-value{
Age ,2 yrs 0.14 (0.07–0.21) – 1.32 (0.4–8.05) – 0.14 (0.08–0.35) –
$2 yrs 0.16 (0.1–0.44) 0.01 2.37 (1.01–7.33) 0.09 0.21 (0.12–0.64) 0.01
Sex Male 0.17 (0.09–0.45) – 2.18 (0.73–7.54) – 0.21 (0.12–0.57) –
Female 0.14 (0.09–0.24) 0.08 1.48 (0.49–7.53) 0.27 0.15 (0.09–0.39) 0.04
HIV status Pos 0.14(0.09–0.24) – 1.4 (0.47–5.61) – 0.15 (0.09–0.29) –
Neg 0.17 (0.09–0.52 0.09 2.49 (0.8–8.89) 0.07 0.2 (0.1–0.84) 0.01
Z-score #22 0.14 (0.09–0.37) – 1.75 (0.6–6.46) – 0.18 (0.09–0.49) –
.–2 0.15 (0.09–0.45) 0.45 2.49 (0.78–9–87) 0.32 0.21 (0.11–0.79) 0.20
History contact yes 0.17 (0.10–0.–36) 2.48 (0.99–7.39) 0.19 (0.10–0.56)
no 0.15 (0.09–0.37) 0.56 1.77 (0.53–8.18) 0.37 0.19 (0.10–0.54) 0.77
Living PTB+ * yes 0.12 (0.1–0.25) 1.91 (0.63–4.35) 0.17 (0.09–0.55)
no 0.15 (0.09–0.37) 0.51 1.77 (0.53–8.18) 0.51 0.19 (0.1–0.54) 0.79
Clinical TB** yes 0.15 (0.10–0.41) 2.28 (0.73–7.45) 0.18 (0.1–0.56)
no 0.15 (0.08–0.34) 0.69 1.91 (0.52–7.53) 0.56 0.19 (0.1–0.53) 0.68
Follow–up status Healthy*** 0.16(0.09–0.39) – 2.65 (0.95–8.8) – 0.19(0.11–0.55) –
Ill 0.16 (0.08–0.35) 0.59 1.08 ((0.33–2.68) 0.04 0.24 (0.1–0.58) 0.37
Died 0.11 (0.05–0.2) 0.01 1.02 (0.19–4.39) ,0.01 0.15 (0.07–0.4) 0.18
Comparison of median IFN-c in subgroups of children, finding lower median levels in response to specific TB antigens in children ,2 years, girls and HIV infected and
lower median mitogen responses in children who subsequently died.
{Wilcoxon’s rank-sum test used to test differences in median IFN-c between subgroups of children, p,0.05 considered significant.
IQR: interquartile range.
*Living PTB+ defined as living in the same household as a person with smear positive pulmonary TB.
**Clinically diagnosed with TB and put on anti-TB therapy.
***Subcategory ‘‘healthy’’ used for comparison both for ‘‘ill’’ and ‘‘died’’.
doi:10.1371/journal.pone.0037851.t003
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and indeterminate QFT results, using 95% confidence intervals to
quantify uncertainty. Risk factors that could potentially be
associated with the performance of the test were identified from
previous studies (age, sex, HIV status, nutritional status and
contact history).
Kaplan Meier failure estimates, odds ratios and log-rank test
were used to illustrate and quantify the difference in mortality
according to QFT results. A p-value of ,0.05 was considered
statistically significant.
Results
Study Population
From April 2008 to June 2010 4713 children were screened,
347 children were eligible according to our inclusion criteria and
211 children with TB suspect signs and symptoms were included
(figure 1). 107 Ziehl-Neelsen smear microscopy positive adults
were screened, 90 with either positive culture and/or positive
fluorescence microscopy were included. Characteristics of the
study populations are shown in table 1.
Four children were culture positive, two of whom were also
fluorescence microscopy positive. In adults 70 were culture and
fluorescence microscopy positive, whilst an additional 4 were
positive by culture only and 16 by microscopy only.
Based on the above and the criteria in box S2, 33/211 (16%) of
children were classified as ‘‘confirmed TB’’, 85/211 (40%)
‘‘possible TB’’ and 93/211 (44%) ‘‘not TB’’. All 90 adults were
classified as ‘‘confirmed TB’’.
TST Results
TST results were available for 197 children (6% positive) and 74
adults (85% positive). Two of four children with TST indurations
measuring 5–9 mm were considered TST positive because they
were HIV positive. The one adult with an induration of 5–9 mm
was HIV negative.
QFT Results
QFT results were positive in 26 (12%), negative in 128 (61%)
and indeterminate in 57 (27%) children. Amongst adults 73 (81%)
were QFT positive, 14 (16%) negative and 3 (3%) indeterminate.
One of the indeterminate results in children was due to high
negative control (.8 U/ml), the remaining indeterminate results
in children and adults were due to low response in the positive
control.
The median levels of IFN-c were significantly lower in children
compared to adults, especially in response to the TB antigens
(table 2). Even children with a positive QFT result had a lower
median IFN-c after antigen stimulation (2.08 U/ml) than adults
with a positive QFT (4.09 U/ml), p = 0.03 (data not shown). The
median IFN-c in response to TB antigens was significantly lower
in children under 2 years, in girls and HIV positive children
(table 3). Amongst children with a positive QFT test, HIV positive
children still had a significantly lower median IFN-c response to
TB antigens than HIV negative children (data not shown).
Children who died before discharge or during the follow-up
period, as well as those who were still ill at 6 month follow-up had
lower median IFN-c in the positive control at base-line compared
to those who had regained their health.
Sensitivity of QFT and TST for Diagnosing Active TB
Amongst children, clinically diagnosed with TB and started on
anti-TB treatment by the local physician, we found a sensitivity of
QFT and TST of only 18% and 12% respectively. Amongst
children with ‘‘confirmed TB’’ we found a sensitivity of QFT and
TST of 19% and 6% respectively. The sensitivity of QFT and
TST in children with ‘‘possible TB’’ was 24% and 9%, and in
children with ‘‘not TB’’ 10% and 3% (table 4).
The specificity of QFT and TST in children was 90% and 98%
respectively. The positive predictive value of QFT and TST in
children for having confirmed TB was 42% and 40%, whilst the
negative predictive value was 73% and 75% respectively.
In contrast, the diagnostic sensitivity of QFT and TST amongst
adults with confirmed TB was notably higher than in children at
86% and 89% (table 4). Sensitivity of QFT was significantly lower
in HIV positive adults 67% (16/24), compared to HIV negative
adults 91% (57/63), p = 0.007 (data not shown). The sensitivity of
TST in adults was not affected by HIV status. The specificity in
adults was not calculated since the inclusion criteria was confirmed
TB.
Risk Factors Association with Positive and Indeterminate
QFT Results
Logistic regression analysis was used in order to identify possible
causes for the low positivity rate and high indeterminate rate of
QFT in children (Table 5 and 6).
Neither sex, malnutrition nor HIV infection, were associated
with either positive or indeterminate QFT results in the
unadjusted or adjusted analysis. Surprisingly, history of TB
Table 4. Sensitivity of Quantiferon TB Gold In-Tube test and Tuberculin Skin test in children and adults.
QFT positive TST positive p-value{
Children n/all tested* (%) 95% CI n/all tested (%) 95% CI
Clinical TB diagnosis 11/60 (18.3) 8.4–28.3 8/69 (11.6) 3.9–19.3 0.28
Confirmed TB 5/27 (18.5) 3.4–33.6 2/31 (6) 22.4–15.3 0.16
Possible TB 14/59 (23.7) 12.7–34.8 7/77 (9.1) 2.6–15.6 0.02
Not TB 7/68 (10.3) 3.0–17.6 3/89 (3.4) 20.4–7.2 0.03
Adults
Confirmed TB 73/87 (83.9) 76.0–91.8 63/74 (85.1) 76.8–93.4 0.85
Sensitivity of QFT and TST according to TB status in children and adults, showing low sensitivity of both T-cell based test in children, irrespective of TB classification,
compared to adults with confirmed TB.
*Sensitivity analysis of QFT excludes indeterminate results.
{Difference between sensitivity in QFT and TST tested using two-sample test of proportion.
doi:10.1371/journal.pone.0037851.t004
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contact was not associated with a positive QFT result, even after
adjusting for confounders in the multivariable analysis.
Age seemed to influence the test performance as children ,2
years were more likely to have an indeterminate result (adjusted
OR 2.39, p = 0.01).
In adults HIV infection was negatively associated with a positive
QFT result (adjusted OR 0.25, p = 0.04) (table 7), whilst we found
no effect of age, sex or HIV status when analysing risk factors for
an indeterminate result (table 8). We were unable to determine
association with BMI as none with a BMI.18.5 had an
indeterminate result.
Mortality
Eleven children died during admission, whilst an additional 28
children died during the follow up period, resulting in an overall
mortality of 19%. An indeterminate QFT result at baseline was
associated with subsequent high childhood mortality (adjusted OR
3.87, p = 0.003, data not shown) and the cumulative mortality was
significantly higher in children with an indeterminate QFT result
(33%) compared to a determinate result (13%), p,0.001 (figure 2).
Discussion
The main findings of this study were a low sensitivity of both
QFT and TST for diagnosing active TB in children as well as a
high QFT indeterminate rate which was associated with high
subsequent mortality.
We found a surprisingly low sensitivity of QFT in children
with confirmed TB (19%) compared to adults with confirmed
TB (84%). The sensitivity of TST was similarly poor in children
(6%) compared to adults (85%). Using other criteria for
Table 5. Risk factors association with positive QFT results in children.
QFT positive (n)
(N) n/N (%) OR (95% CI) p-value{ Adj OR1 (95% CI) p-value{
Age $2 yrs 17/105 (16.2) 1 – 1 –
,2 yrs 9/49 (18.4) 1.16 (0.48–2.84) 0.73 0.93 (0.34–2.58) 0.89
Sex Female 11/62 (17.7) 1 – 1 –
Male 15/92 (16.3) 0.90 (0.38–2.12) 0.82 0.95 (0.37–2.43) 0.92
HIV status Neg 19/99 (19.2) 1 – 1 –
Pos 6/54 (11.1) 0.53 (0.20–1.41) 0.20 0.61 (0.21–1.77) 0.37
Z-score .22 11/60 (18.3) 1 – 1 –
#22 13/76 (11.9) 0.92 (0.38–2.23) 0.69 1.00 (0.39–2.59) 0.99
History contact No 15/93 (16.1) 1 – 1 –
Yes 11/60 (18.3) 1.17 (0.50–2.75) 0.72 1.37 (0.55–3.41) 0.49
Living PTB+ * No 15/93 (16.3) 1 – 1 –
Yes 7/27 (25.9) 1.82 (0.65–5.06) 0.25 2.83 (0.89–9.03) 0.08
Risk factor analysis using logistic regression analysis found no association between known risk factors and a positive QFT result in children.
OR: unadjusted odds ratio from univariable analysis.
Adj OR: adjusted odds ratio, adjusted for age, sex, HIV, z-score and contact TB case.
{p-value for the odds ratios.
*Compares living with a case of smear positive TB case to those reporting no contact at all.
doi:10.1371/journal.pone.0037851.t005
Table 6. Risk factors association with indeterminate QFT results in children.
QFT indeterminate (n)
(N) n/N (%) OR (95% CI) p-value{ Adj OR (95% CI) p-value{
Age $2 yrs 29/134 (21.6) 1 – 1 –
,2 yrs 28/77 (36.4) 2.07 (1.11–3.85) 0.02 2.39 (1.22–4.68) 0.01
Sex Female 25/87 (28.7) 1 – 1 –
Male 32/124 (25.8) 0.86 (0.47–1.59) 0.64 0.79 (0.40–1.54) 0.49
HIV status Neg 32/131 (24.4) 1 – 1 –
Pos 24/78 (30.8) 1.38 (0.74–2.57) 0.32 1.28 (0.63–2.63) 0.50
Z-score .22 19/79 (24.1) 1 – 1 –
#22 33/109 (30.3) 1.37 (0.71–2.65) 0.35 1.09 (0.53–2.21) 0.82
Risk factor analysis using logistic regression analysis found increased odds of an indeterminate result in children ,2 years.
OR: unadjusted odds ratio from univariable analysis.
Adj OR: adjusted odds ratio, adjusted for age, sex, HIV and z-score.
{p-value for the odds ratios.
doi:10.1371/journal.pone.0037851.t006
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diagnosing TB, such as the clinical TB diagnosis or by including
children with possible TB in the group of TB cases, did not
alter the overall picture of an extremely low sensitivity. In
addition the positive and negative predictive values of QFT in
children were low.
We found a high specificity ($ 90%) for both QFT and TST,
either suggesting that false positive results due to latent TB or
BCG vaccination did not influence the performance of the tests or
reflecting the overall poor performance of the test, with low
proportions of positive results in this population.
The few existing previous paediatric studies have reported QFT
sensitivity for active TB varying from 50%–100% [12]. To our
knowledge only one other study has evaluated QFT in a high
burden setting and they found only 8 children with confirmed TB
and a sensitivity of 63% [13]. Studies evaluating T-SpotH-TB,
another commercially available IGRA (Oxford Immunotec,
Abingdon, UK), in children in a high endemic setting are equally
few, one study in South Africa study with 10 culture confirmed
cases of TB, found a sensitivity of 50% [14].
We found only 12 children with a positive TST, which is
surprising given that 72 (35%) reported contact to person with TB
and 92.9% were BCG vaccinated. The sensitivity of TST (6%) was
even lower than QFT.
Infants are known to have poor production of cytokines, such as
IFN-c, even beyond infancy [15] and there is evidence that an
effective antigen specific response to the MTB infection is delayed
and less effective in infants compared to adults [16] which could
explain our comparatively low positivity rate. Not only young age
[13] but also HIV infection [17] and malnutrition, [18] were
expected to affect test sensitivity, due to immature immune
response or suppression of T-cell response. We found no clear
association in our risk factor analysis between these factors and the
QFT positivity rate, possibly due to small sample size, however we
did find reduced IFN-c responses in children ,2 years, HIV
infected and children who were still ill or had died by 6 month
follow-up. Children in low-income settings often present with
severe TB after a long period of illness, and consequent suboptimal
immune response [19,20]. These findings suggest that the
performance of QFT as well as TST, in these children with
chronic and severe illness, were affected by immature or impaired
immunity and progressive exhaustion of T-cells ability to react
adequately to antigen response [21].
Table 7. Risk factors association with positive QFT result in adults.
QFT positive (n)
(N) n/N (%) OR (95% CI) p-value{ Adj. OR (95% CI) p-value{
Age years* – 1.0 (0.96–1.04) 0.93 0.10 (0.95–1.04) 0.89
Sex Female 11/16 (68.8) 1 1
Male 62/71 (87.3) 3.13 (0.88–11.12) 0.08 2.07 (0.49–8.81) 0.33
HIV status Neg 57/63 (90.5) 1 1
Pos 16/24 (66.7) 0.21 (0.06–0.70) 0.01 0.25 (0.07–0.92) 0.04
BMI $18.5 28/33 (84.9) 1 1
,18.5 45/54 (83.3) 0.89 (0.27–2.94) 0.85 0.81 (0.23–2.84) 0.74
Risk factor analysis using logistic regression analysis found lower odds of a positive QFT result in HIV infected adults.
OR: odds ratio from univariable analysis.
Adj. OR: adjusted odds ratio adjusted for age, sex, HIV infection and BMI.
*Odds ratio calculated as per year increase in age.
{p-value for the odds ratios.
doi:10.1371/journal.pone.0037851.t007
Table 8. Risk factors association with indeterminate QFT result in adults.
QFT indeterminate (n)
(N) n/N (%) OR (95% CI) p-value{ Adj. OR (95% CI) p-value{
Age years* – 1.06 (0.99–1.15) 0.10 1.10 (0.99–1.22) 0.07
Sex Female 2/18 (11.1) 1 – 1 –
Male 1/72 (1.4) 0.11 (0.01–1.32) 0.08 0.02 (0.00–1.28) 0.07
HIV status Neg 2/65 (3.1) 1 – 1 –
Pos 1/25 ((4) 1.31 (0.11–15.15) 0.83 0.47 (0.01–17.02) 0.68
BMI ** $18.5 0/33 – – – –
,18.5 3/57 (5.3) – – – –
Risk factor analysis using logistic regression analysis found no association between suspected risk factors and an indeterminate QFT result in adults.
OR: odds ratio from univariable analysis.
Adj. OR: adjusted odds ratio adjusted for age, sex, HIV infection and BMI.
*Odds ratio calculated as per year increase in age.
**Logistic regression analysis not possible for association between BMI and indeterminate result, since there are no indeterminate results in those with BMI $18.5.
{p-value for the odds ratios.
doi:10.1371/journal.pone.0037851.t008
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Due to the lower levels of IFN-c in response to specific antigens
seen in HIV infected and young children it has been suggested that
a lower cut-off value for a positive QFT for children may be
relevant [22]. However applying a cut-off of 0.26 U/ml to our
data only increased the number of positives by two, both of whom
were classified ‘‘not TB’’. Thus our study does not indicate added
value of a lower cut-off in terms of sensitivity of QFT for active
TB.
The poor sensitivity of, not only QFT but also TST, could also
be explained by misclassification and over-diagnosis of TB
however we included microbiological confirmation, good clinical
response to treatment, in addition to either typical CXR or clinical
features, which is in accordance with the recommendations of the
recent expert consensus report on evaluating TB diagnostics in
children [23].
Like other studies including TB suspect children we found only
a small proportion of culture confirmed cases (2%). In the four
culture confirmed cases of TB there was only one QFT and one
TST positive result (in the same child), indicating that, rather than
a classification problem, the performance of T-cell based assays in
this particular group of children is suboptimal. Two of the
remaining children with culture confirmed TB, were both HIV
positive and severely malnourished, and it reasonable to conclude
that they were not able to mount an adequate immune response.
Our results highlight the difficulties in diagnosing TB in
children and we cannot conclude whether QFT suffers from
extremely low sensitivity in young children with active TB in a
high burden country or whether TB was over-diagnosed in these
very sick children. However in light of the review by Mandalakas
et al [12] which found that sensitivity of IGRAs and TST was
lower in children ,5 years, HIV positive children and in low-
middle income countries, our finding of low sensitivity is not
unlikely.
In adults we found a sensitivity of 84% which compares to the
pooled sensitivity of 80% in a recent review of IGRA studies [8]
and in line with another Tanzanian study [17] and the review by
Metcalfe [24], we also found a lower sensitivity amongst HIV
positive adults.
We found a high indeterminate rate in children (27%)
compared to adults (3%) (p,0.01) with higher rates amongst
children ,2 years and in children who subsequently died after
inclusion. Surprisingly our data did not support a significant
association with HIV infection or malnutrition possibly due to low
numbers.
Indeterminate rates in other paediatric QFT studies range from
0–35% [13,25], high rates correlated with young age [26],
immune suppression [25] and malnutrition [27]. Thomas et al
[27] found, in a study in Bangladesh that indeterminate results
were associated not only with malnutrition but also with helminth
infection, suggesting that children in a generally poor nutritional
state with added infections are less likely to have a determinate
QFT result. Hook worm and schistosomiasis are known to be
highly prevalent amongst school children in the study area [28]
and we can reasonably assume that many of the study participants
were co-infected, which may have influenced the performance of
QFT [29].
In our study 58% of children were defined as being
malnourished. Malnutrition leads to an impaired cellular immu-
nity which could affect the performance of the IGRA tests [18,30]
however several studies conducted in populations with significant
malnutrition [13,31], including the current study, did not find
malnutrition to be associated with reduced positivity rates or
increased indeterminate results. It is possible that weight-for-age z-
score is not the optimal measure for assessing the effect of
malnutrition on IGRA responses. A study of Peruvian adults found
that malnutrition as measured by corrected arm muscle area, but
not BMI or body fat, was associated with decreased TST positivity
[32].
No previous paediatric studies have shown that an indetermi-
nate result is a risk factor for death. To our knowledge only one
Figure 2. Childhood mortality according to Quantiferon TB Gold In-Tube result. Childhood mortality recorded during admission and at 6
month follow-up, according to QFT results. Children who did not attend scheduled follow-up at 6 months were traced and follow-up visits were
conducted in their homes within 7–12 months of inclusion. Both the mortality during admission and the overall mortality in children with an
indeterminate QFT result was significantly higher than in children with a determinate QFT result, p,0.001. * One of 154 children with a determinate
QFT result did not have follow-up data.
doi:10.1371/journal.pone.0037851.g002
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study in TB-suspect HIV positive adults in Uganda has shown that
mortality was higher in those with an indeterminate T-SPOT.TB
result [33]. It is reasonable to hypothesise that the children who
died after inclusion were severely ill and therefore unable to mount
an appropriate immune response. Thus, we suggest that the care
for children with indeterminate results should be intensified with
extensive diagnosis and treatment.
We found a low indeterminate rate of 3% amongst adults. Even
amongst the HIV positive adults, the indeterminate rate was only
4% which contrasts to other studies, including HIV infected
participants, where indeterminate rates reach as high as 21% [34].
HIV infection is known to be associated with lower positivity rates
[35] and our data support these findings.
The samples of both children and adults were taken and
processed concurrently, at the same hospital using the same staff,
procedures and equipment. As such, it is most unlikely that the
poor performance in children was due to technical errors.
Our study suggests that T-cell based assays, such as QFT and
TST, have poor performance in children with immature or
impaired immune systems and that indeterminate results are a
predictor for death. With a sensitivity of 19% amongst children
with confirmed TB and indeterminate rate of 27%, QFT is not the
answer for providing clinicians with a reliable tool for diagnosing
childhood TB in a high burden setting. This conclusion is in line
with recent reports that underline that IGRA cannot be used as a
test to exclude active TB in children [36], that use of IGRAs is not
recommended in children under 5 years [7] and according to
WHO should not be used in low and middle income countries at
all [37]. Whether low sensitivity is due to poor antigen response,
misclassification or over-diagnosis remains a major challenge for
the evaluation of any new diagnostic test for TB in children
however the evidence of high mortality in this vulnerable group
serves to underline the continued importance of research in this
field.
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